tradingkey.logo

Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction

ReutersFeb 4, 2026 10:11 PM


Overview

  • Agricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yr

  • Adjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairment

  • Company to explore strategic options, including potential sale, to enhance shareholder value


Outlook

  • FMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpoint

  • Adjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%

  • FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decrease


Result Drivers

  • PRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressures

  • NEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue decline


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Miss

$1.08 bln

$1.15 bln (14 Analysts)

Press Release: ID:nPn4p3X6ra

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI